Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
doi: 10.3389/fendo.2025.1570603 Received 03 February 2025 Accepted 29 April 2025 Published 21 May 2025 Volume 16 - 2025 Edited by Jared Rutter, The University of Utah, United States Reviewed by Steven Patterson, Glasgow Caledonian University, United Kingdom Elena Jimenez Marti, University of Valencia, Spain Nigel Irwin, Ulster University, United Kingdom Updates Copyright 2025 Koefoed-Hansen, Helsted, Kizilkaya, Lund, Rosenkilde and Gasbjerg
IJRISS 7 , 2636 (2023)
Their willingness to share their experiences is paving the way for a new era of precision medicine in obesity treatment
Benefits: Tirzepatide is an innovative dual receptor agonist that targets both GIP and GLP-1 receptors
Patient-reported reasons for GLP-1 treatment discontinuation 4 GLP-1 challenges in focus Learn more about Haleons trusted wellness solutions Fit in fiber Find out how Haleon products can help your patients with their fiber gaps
:format(webp))
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)